Atea Historical Income Statement
| AVIR Stock | USD 3.46 0.16 4.85% |
Historical analysis of Atea Pharmaceuticals income statement accounts such as Interest Income of 30.7 M, Depreciation And Amortization of 436.8 K or Interest Expense of 13.5 M can show how well Atea Pharmaceuticals performed in making a profits. Evaluating Atea Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Atea Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Atea Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Atea Pharmaceuticals is a good buy for the upcoming year.
Atea |
About Atea Income Statement Analysis
Atea Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Atea Pharmaceuticals shareholders. The income statement also shows Atea investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Atea Pharmaceuticals Income Statement Chart
Add Fundamental
Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Total Revenue
Total revenue comprises all receipts Atea Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Atea Pharmaceuticals. It is also known as Atea Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Atea Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Atea Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.At this time, Atea Pharmaceuticals' Total Other Income Expense Net is relatively stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 213K | 11.2M | 29.2M | 30.7M | Net Interest Income | 213K | 11.2M | 29.2M | 30.7M |
Atea Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Atea Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atea Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 574K | 83K | 213K | 11.2M | 29.2M | 30.7M | |
| Interest Income | 574K | 83K | 213K | 11.2M | 29.2M | 30.7M | |
| Selling General Administrative | 4.4M | 21.6M | 45.8M | 48.7M | 49.9M | 31.8M | |
| Other Operating Expenses | 14.6M | 59.7M | 213.0M | 130.7M | 164.2M | 108.5M | |
| Operating Income | (14.6M) | (11.0M) | 138.4M | (130.7M) | (164.2M) | (156.0M) | |
| Net Income From Continuing Ops | (14.0M) | (10.9M) | 121.2M | (115.9M) | (136.0M) | (129.2M) | |
| Ebit | (14.6M) | (11.0M) | 138.4M | (130.7M) | (120.0M) | (114.0M) | |
| Research Development | 10.2M | 38.0M | 167.2M | 81.9M | 132.8M | 80.1M | |
| Ebitda | (14.6M) | (11.0M) | 138.4M | (130.4M) | (119.6M) | (113.6M) | |
| Total Operating Expenses | 14.6M | 59.7M | 213.0M | 130.7M | 94.1M | 95.6M | |
| Income Before Tax | (14.0M) | (10.9M) | 138.6M | (119.5M) | (134.9M) | (128.2M) | |
| Total Other Income Expense Net | 574K | 83K | 213K | 11.2M | 29.2M | 30.7M | |
| Net Income Applicable To Common Shares | (14.0M) | (10.9M) | 121.2M | (115.9M) | (104.3M) | (99.1M) | |
| Net Income | (13.5M) | (10.9M) | 121.2M | (115.9M) | (136.0M) | (129.2M) | |
| Income Tax Expense | (574K) | (83K) | 17.4M | (3.6M) | 1.0M | 967.1K |
Pair Trading with Atea Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
| 0.68 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.76 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.68 | LLY | Eli Lilly Sell-off Trend | PairCorr |
Moving against Atea Stock
| 0.72 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.59 | GILD | Gilead Sciences | PairCorr |
| 0.53 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.44 | LPCN | Lipocine | PairCorr |
| 0.43 | MNOV | MediciNova | PairCorr |
The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.
The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Atea Stock Analysis
When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.